As you can tell, our core style is to provide actionable and unambiguous ideas from our independent research. If you share this investment style, check out Envision Early Retirement. It provides at least 1x in-depth article per week on such ideas.We have helped our members not only to beat S&P 500 but also to avoid heavy drawdowns despite the extreme volatilities in BOTH the equity AND bond market.Join for a trial and see if our proven method can help you too. ...

Key Takeaways AbbVie stock is up 22.5% in 2025, beating its industry, sector and the S&P 500 index.Strong sales of Skyrizi and Rinvoq are replacing Humira and driving top-line growth.Acquisitions in immunology, oncology and neuroscience strengthen AbbVie's pipeline.AbbVie (ABBV) has gained 22.5% so far this year against a decrease of 0.1% for the industry. The stock has also outperformed the sector and the S&P 500 index, as seen in the chart below.ABBV Stock Outperforms Industry, Sector & S&P 500Image Sourc ...

AbbVie Inc. (NYSE:ABBV) is included among the 13 Best Consistent Dividend Stocks to Buy Now. AbbVie (ABBV)'s Dividend Track Record: How It Became a Leader in Consistent Dividends AbbVie Inc. (NYSE:ABBV) is an Illinois-based pharmaceutical company. It has delivered strong results in 2025, easily beating the broader market. Much of this momentum comes from solid growth in sales and adjusted earnings, driven largely by its autoimmune treatments Rinvoq and Skyrizi. The stock has surged by nearly 22% since th ...

In this article, we will take a look at some of the best dividend stocks with consistent payouts.Investors have been rushing into high-dividend stocks, attracted by the promise of strong payouts as interest-rate cuts are anticipated later this year.According to Purpose Investments Inc., the five largest dividend-focused exchange-traded funds saw inflows of $17.5 billion by mid-July, almost ten times higher than at the beginning of 2024. However, the challenge for income seekers is that fewer US companies ar ...

Dividends are powerful portfolio boosters, and AbbVie is a dividend dynamo.AbbVie (ABBV -0.32%) is a drug company, spun off from Abbott Laboratories in 2013, that you might want to consider for your long-term portfolio. One of the biggest green flags for investing in the company is its dividend. AbbVie's recent dividend yield was a solid 3.1% -- the S&P 500's recent yield was a mere 1.2% -- and better still, it has been growing, with plenty of room to keep doing so.Over the past five years, AbbVie hiked its ...

Key Takeaways AbbVie settled with generic drugmakers, extending Rinvoq exclusivity until April 2037.Rinvoq sales jumped 48% to $3.75B, now 13% of AbbVie's total revenue.New indications may add $2B to Rinvoq's peak sales, reinforcing AbbVie's growth outlook.Shares of AbbVie (ABBV) rose over 4% to a record high on Thursday after the company announced that it had settled patent litigation with all generic manufacturers who had sought the FDA’s approval for generic versions of its blockbuster immunology drug, R ...

Group 1 - The company is experiencing a decline in sales of its previously successful drug, Humira [1]

Core Viewpoint - The U.S. government, led by President Trump, is pressuring major pharmaceutical companies to lower drug prices in the U.S. by adhering to the "most-favored-nation" (MFN) pricing policy, which aims to align U.S. drug prices with the lowest prices in other developed countries [1][2][3] Group 1: Government Actions - President Trump has set a deadline of September 29 for pharmaceutical companies to comply with the MFN policy [2] - Multiple federal departments are being mobilized to support this initiative, indicating a coordinated effort to enforce the price reductions [2][3] Group 2: Pharmaceutical Companies Involved - Major pharmaceutical companies receiving Trump's letter include Eli Lilly (LLY.US), Pfizer (PFE.US), Merck (MRK.US), Gilead (GILD.US), Bristol-Myers Squibb (BMY.US), Johnson & Johnson (JNJ.US), Regeneron (REGN.US), Amgen (AMGN.US), AbbVie (ABBV.US), and several European firms such as Merck KGaA, Sanofi (SNY.US), GlaxoSmithKline (GSK.US), AstraZeneca (AZN.US), Novo Nordisk (NVO.US), Roche (RHHBY.US), and Novartis (NVS.US) [1] Group 3: Implications of High Drug Prices - The long-term high drug prices in the U.S. create significant pressure on both public welfare and government finances, making the MFN policy a direct and quantifiable approach to reduce costs [3] - The lack of price regulation in the U.S. compared to other countries contributes to higher drug prices, as U.S. pharmaceutical companies can raise prices without negotiation [3]

文｜胡香赟 受消息影响，9月11日，A股、H股创新药概念集体走低，百济神州、荣昌生物等多只个股走弱；港股多 家药企跌超10%。伴随着对消息的进一步解读，昨日午间，创新药板块局部回暖，涨幅收窄。12日上午 创新药板块震荡走强，盘中恒生生物科技指数大幅拉升。 BD交易是当下中美药企之间的核心合作形式，仅今年上半年，中国创新药License-out总金额达608亿美 元，首付款26亿美元。而特朗普之所以推出这项草案，也是因为近两年跨国药企大量购买中国的创新药 管线，"却对研发同类型药物的美国生物科技公司不屑一顾"，引起了部分美国投资者的不满。 不过，由于该草案牵涉的利益方过于复杂，行业内主流观点对该草案能否落地存疑。有披露过大额BD 交易的药企人士表示：如今中国创新药出海的"主要亮点就是BD"，若草案真的落地，"不会是好事"。 但是，限制中国药企做BD，本质也会限制美国大型药企的发展，相当于"杀敌一千自损八百"。 植德律所投资并购部合伙人郭晓兴认为，消息中提到的部分限制领域"令人意外"；但考虑各方利益博 弈，即使法案最终落地，可能也只是涉及细胞治疗、人类遗传资源利用等最敏感的领域，其他交易仍有 望正常进行。 草案拟 ...

Core Insights - The in vivo CAR-T therapy market is rapidly gaining traction, with significant mergers and acquisitions by major multinational corporations (MNCs) indicating a strategic shift towards this innovative treatment approach [1][2][3] - The advancements in delivery vector technologies are driving the development of in vivo CAR-T therapies, with a focus on improving targeting efficiency and safety [3][4] Group 1: Mergers and Acquisitions - AstraZeneca acquired EsoBiotec for $1 billion to enhance its in vivo CAR-T therapy portfolio [1][2] - AbbVie announced the acquisition of Capstan Therapeutics for up to $2.1 billion, marking a significant investment in the in vivo CAR-T space [1][2] - Gilead's Kite acquired Interius for $350 million, further expanding its capabilities in cell therapy [1][2] Group 2: Technology Platforms - EsoBiotec's core technology is the engineered nanobody lentivirus (ENaBL) platform, which enhances the specificity of immune cell transfection [4] - Interius utilizes a lentiviral vector to deliver CAR genes, generating CAR-T and CAR-NK cells directly in vivo for targeting B-cell malignancies [3][4] - The mRNA-LNP (lipid nanoparticle) delivery system is gaining attention for its safety profile, allowing for transient CAR expression without permanent genetic modification [7][8] Group 3: Clinical Developments - EsoBiotec's product ESO-T01 has shown promising clinical trial results for multiple myeloma, indicating potential effectiveness in treating relapsed or refractory cases [15][17] - Capstan Therapeutics' candidate CPTX2309 is currently in Phase I trials for autoimmune diseases, showcasing the therapeutic potential of the LNP delivery approach [8][9] Group 4: Industry Trends - The shift from ex vivo to in vivo CAR-T therapies is reshaping the ecosystem, with increased collaboration among technology partners and a focus on delivery efficiency [3][6] - The reliance on upstream CXO (Contract Research Organization) services is significant, with over 65% of CGT (Cell and Gene Therapy) projects involving CXO participation [6][12] - The industry is witnessing a dual approach, with companies like AbbVie investing in both lentiviral and mRNA-LNP technologies to mitigate risks associated with single technology pathways [16][17]